Lumida
/BBNX
⌘K
Beta Bionics Inc

Beta Bionics Inc

BBNX
$16.57USD-0.12%-0.02 today

MARKET CAP

745.5M

P/E (TTM)

FWD P/E

DAY RANGE

$16 – $17

52W RANGE

$9
$33

AI Summary

Stalk
StalkMedium

BBNX remains in a Stage 2 uptrend with successive higher highs and higher lows above rising EMAs. The medium-term bias is bullish, but short-term price is extended above EMAs and in extreme overbought RSI territory, warranting patience. Preferred entries are on pullbacks into the 9- and 20-day EMA support zone for continuation participation.

  • Net sales grew 38% YoY to $32M in Q2 2026, led by new patient starts
  • Pharmacy channel now reimburses ~37–39% of patient starts, lowering costs
  • Operating expenses jumped 37% YoY to $44.5M, pressuring profitability
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2025TREND
Sales, Adj.$100.3M
YoY %
P / Sales12.3x
EV / Sales12.4x
Gross Profit, Adj.$55.5M
YoY %
Margin %55.4%
EV / Gross Profit22.4x
EBITDA, Adj.$-70.1M
YoY %
Margin %-69.9%
EV / EBITDA-17.8x
EBIT$-71.7M
YoY %
Margin %-71.5%
EV / EBIT-17.4x
Net Income$-73.2M
YoY %
Net Margin-73.0%
EPS (GAAP)-$1.81
YoY %